

Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1. Product identifier

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Product Code(s) PZ03767
Trade Name: Not established
Chemical Family: Not determined

Contains Diclofenac epolamine

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended Use topical analgesic Non-steroidal, anti-inflammatory drug (NSAID)

1.3. Details of the supplier of the safety data sheet

Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095

1.4. Emergency telephone number

Emergency Telephone CHEMTREC (24 hours): 1-800-424-9300

Section 2: HAZARDS IDENTIFICATION

2.1. Classification of the substance or mixture

Reproductive toxicity Category 1B - (H360D)

2.2. Label elements

Signal word Danger

Hazard statements H360D - May damage the unborn child

Precautionary Statements

P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P280 - Wear protective gloves/protective clothing/eye protection/face protection
P308 + P313 - IF exposed or concerned: Get medical advice/attention



2.3. Other hazards

Other hazards An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 2 / 13
Version 2

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 Substances

Hazardous

Chemical Name	EC No	CAS No	Weight-%	Classification according to Regulation (EC) No. 1272/2008 [CLP]	REACH Registration Number
Diclofenac epolamine	Not Listed	119623-66-4	1.3	Acute Tox.3 (H301) Repr.1B (H360D) Aquatic Chronic 4 (H413)	
Titanium dioxide	236-675-5	13463-67-7	*	Not Listed	
Sodium polyacrylate	Not Listed	9003-04-7	*	Not Listed	
Kaolin	310-194-1	1332-58-7	*	Not Listed	

NonHazardous

Chemical Name	EC No	CAS No	Weight-%	Classification according to Regulation (EC) No. 1272/2008 [CLP]	REACH Registration Number
Water	231-791-2	7732-18-5	*	Not Listed	
Tartaric acid	201-766-0	87-69-4	*	Not Listed	
Sorbitol solution	200-061-5	50-70-4	*	Not Listed	
Propylparaben	202-307-7	94-13-3	*	Not Listed	
Povidone	Not Listed	9003-39-8	*	Not Listed	
Polysorbate 80	500-019-9	9005-65-6	*	Not Listed	
Methyl-p-hydroxybenzoate	202-785-7	99-76-3	*	Not Listed	
Gelatin	232-554-6	9000-70-8	*	Not Listed	
Fragrance	Not Listed	NOT ASSIGNED	*	Not Listed	
Edetate disodium	205-358-3	139-33-3	*	Not Listed	
Dihydroxyaluminum aminoacetate	Not Listed	41354-48-7	*	Not Listed	
Carboxymethylcellulose sodium	Not Listed	9004-32-4	*	Not Listed	
Butylene glycol	203-529-7	107-88-0	*	Not Listed	

Full text of H- and EUH-phrases: see section 16

Additional information

* Proprietary
Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

Section 4: FIRST AID MEASURES

4.1. Description of first aid measures

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 3 / 13
Version 2

Inhalation	Remove to fresh air. Seek immediate medical attention/advice.
Eye contact	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
Skin contact	Wash skin with soap and water. In the case of skin irritation or allergic reactions see a physician.
Ingestion	Clean mouth with water and drink afterwards plenty of water.

4.2. Most important symptoms and effects, both acute and delayed

Most important symptoms and effects For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

4.3. Indication of any immediate medical attention and special treatment needed

Note to physicians None.

Section 5: FIRE-FIGHTING MEASURES

5.1. Extinguishing media

Suitable Extinguishing Media Dry chemical, CO₂, alcohol-resistant foam or water spray.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the chemical Fine particles (such as dust and mists) may fuel fires/explosions.

Hazardous combustion products Formation of toxic gases is possible during heating or fire.

5.3. Advice for firefighters

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

Section 6: ACCIDENTAL RELEASE MEASURES

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

For emergency responders Use personal protection recommended in Section 8.

6.2. Environmental precautions

Environmental precautions Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.
Methods for cleaning up Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 4 / 13
Version 2

Section 7: HANDLING AND STORAGE

7.1. Precautions for safe handling

Advice on safe handling

Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Store as directed by product packaging.

7.3. Specific end use(s)

Specific use(s) Pharmaceutical drug product.

Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1. Control parameters

Exposure Limits

Refer to available public information for specific member state Occupational Exposure Limits.

Diclofenac Sodium

Russia MAC: 0.2 mg/m³

Sorbitol solution

Russia MAC: 10 mg/m³

Tartaric acid

Germany 2 mg/m³
Ceiling / Peak: 4 mg/m³
Germany 2 mg/m³
Switzerland 2 mg/m³
STEL: 4 mg/m³

Gelatin

Russia MAC: 10 mg/m³

Povidone

Russia MAC: 10 mg/m³

Carboxymethylcellulose sodium

Russia MAC: 10 mg/m³

Propylparaben

Russia MAC: 10 mg/m³

Methyl-p-hydroxybenzoate

Russia MAC: 4 mg/m³

Kaolin

ACGIH TLV 2 mg/m³
Bulgaria 3.0 mg/m³
6.0 mg/m³
Denmark 2 mg/m³
Finland 2 mg/m³
France 10 mg/m³
Ireland 2 mg/m³
Poland 10.0 mg/m³
Spain 2 mg/m³
Switzerland 3 mg/m³

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 5 / 13
Version 2

OSHA PEL	15 mg/m ³ 5 mg/m ³ (vacated) TWA: 10 mg/m ³ total dust (vacated) TWA: 5 mg/m ³ respirable fraction
United Kingdom	TWA: 2 mg/m ³ STEL: 6 mg/m ³
Titanium dioxide	
ACGIH TLV	10 mg/m ³
Austria	5 mg/m ³ STEL 10 mg/m ³
Bulgaria	10.0 mg/m ³ 1.0 mg/m ³
Denmark	6 mg/m ³
Estonia	5 mg/m ³
France	10 mg/m ³
Germany	0.3 mg/m ³ multiplied by the material density;except ultrafine particles Ceiling / Peak: 2.4 mg/m ³
Ireland	10 mg/m ³ 4 mg/m ³ STEL: 30 mg/m ³ STEL: 12 mg/m ³
Latvia	10 mg/m ³
Poland	STEL: 30 mg/m ³ 10 mg/m ³
Romania	10 mg/m ³ STEL: 15 mg/m ³
Russia	TWA: 10 mg/m ³
Slovakia	5 mg/m ³
Spain	10 mg/m ³
Switzerland	3 mg/m ³
OSHA PEL	15 mg/m ³ (vacated) TWA: 10 mg/m ³ total dust
United Kingdom	TWA: 10 mg/m ³ TWA: 4 mg/m ³ STEL: 30 mg/m ³ STEL: 12 mg/m ³
Edetate disodium	
Russia	MAC: 2 mg/m ³

Manufacturer OEB Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Diclofenac epolamine

Manufacturer OEB:

OEB2 (control exposure to the range of >100ug/m³ to < 1000ug/m³)

8.2. Exposure controls

Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Environmental exposure controls

No information available.

Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 6 / 13
Version 2

Eye/face protection	Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).
Hand protection	Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).
Skin and body protection	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).
Respiratory protection	Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).
General hygiene considerations	Handle in accordance with good industrial hygiene and safety practice.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1. Information on basic physical and chemical properties

Physical state	Patch
Color	No information available
Molecular formula (MF):	Mixture
Molecular weight	Mixture
Odor	No data available.
Odor threshold	No data available

<u>Property</u>	<u>Values</u>
pH	
Melting point / freezing point	No data available
Boiling point / boiling range	No data available
Flash point	No data available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	No data available
Water solubility	No data available
Solubility(ies)	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Explosive properties	No information available
Oxidizing properties	No information available
Partition Coefficient: (Method, pH, Endpoint, Value)	
<u>Diclofenac epolamine</u>	
Predicted Log P	4.05
<u>Diclofenac Sodium</u>	
Predicted Log P	4.51

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 7 / 13
Version 2

9.2. Other information

Liquid Density

No data available

Bulk density

No data available

Section 10: STABILITY AND REACTIVITY

10.1. Reactivity

Reactivity

No data available.

10.2. Chemical stability

Stability

Stable at normal conditions.

Explosion data

Sensitivity to Mechanical Impact No data available.

Sensitivity to Static Discharge No data available.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

10.4. Conditions to avoid

Conditions to avoid

Fine particles (such as dust and mists) may fuel fires/explosions.

10.5. Incompatible materials

Incompatible materials

As a precautionary measure, keep away from strong oxidizers.

10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

Section 11: TOXICOLOGICAL INFORMATION

11.1. Information on toxicological effects

General Information:

The information included in this section describes the potential hazards of various forms of the active ingredient. The remaining information describes the potential hazards of the individual ingredients.

Long Term:

Animal studies indicate that this material may cause adverse effects on the the developing fetus. Repeat-dose studies in animals have shown a potential to cause adverse effects on blood spleen gastrointestinal system

Known Clinical Effects:

Clinical use has caused effects on the gastrointestinal system, including abdominal pain, nausea, vomiting, diarrhea, constipation, peptic ulcer, acid reflux, and gastrointestinal bleeding. Clinical use has resulted in liver effects. Symptoms may include jaundice, liver function test abnormalities, and hepatitis. Clinical use has caused effects on the nervous system, including drowsiness, anxiety, dizziness, visual disturbances. Serious allergic reactions, including anaphylaxis, have been reported. Clinical use of this drug has caused decreased red blood cell count (anemia), effects on blood forming organs. Clinical use has caused effects on the cardiovascular system, including heart attack (myocardial infarction), stroke. Other nonsteroidal anti-inflammatory drugs (NSAIDs) are known to impact delivery, late fetal development, and lactation.

Acute Toxicity: (Species, Route, End Point, Dose)

Diclofenac epolamine

Rat Oral LD50 55-240 mg/kg

Diclofenac Sodium

Rat Oral LD 50 53-77 mg/kg

Sorbitol solution

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
 Revision date 15-Jan-2020

Page 8 / 13
 Version 2

Rat Oral LD50 15,900 mg/kg
 Mouse Oral LD50 17,800 mg/kg

Povidone

Rat Oral LD50 100 g/kg

Carboxymethylcellulose sodium

Mouse Oral LD50 > 27,000 mg/kg
 Rat Oral LD50 27,000 mg/kg
 Rabbit Dermal LD50 > 2000 mg/kg

Propylparaben

Mouse Oral LD 50 6332 mg/kg
 Mouse Sub-tenon injection (eye) LD 50 200 mg/kg

Methyl-p-hydroxybenzoate

Mouse Oral LD50 >8 g/kg
 Rat Oral LD 50 2100 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg
 Rat Subcutaneous LD50 50 mg/kg

Edetate disodium

Rat Oral LD50 2000-2200 mg/kg

Butylene glycol

Rat Oral LD50 22,800 mg/kg
 Mouse Oral LD50 12,980 mg/kg
 Rabbit Dermal LD50 > 20,000 mg/kg

Chemical Name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg (Rat)	-	-
Titanium dioxide	> 10000 mg/kg (Rat)	-	-
Sorbitol solution	= 15900 mg/kg (Rat)	-	-
Sodium polyacrylate	> 40 g/kg (Rat)	-	-
Povidone	= 100 g/kg (Rat)	-	-
Polysorbate 80	= 34500 µL/kg (Rat)	-	-
Methyl-p-hydroxybenzoate	= 2100 mg/kg (Rat)	-	-
Kaolin	> 5000 mg/kg (Rat)	> 5000 mg/kg (Rat)	-
Edetate disodium	= 2 g/kg (Rat)	-	-
Carboxymethylcellulose sodium	= 27000 mg/kg (Rat)	> 2 g/kg (Rabbit)	> 5800 mg/m ³ (Rat) 4 h
Butylene glycol	= 18610 mg/kg (Rat)	> 20 g/kg (Rabbit)	> 60 ppm (Rat) 8 h

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Diclofenac Sodium

Skin Irritation Positive
 Eye Irritation Positive

Methyl-p-hydroxybenzoate

Skin Irritation Rabbit Non-irritating

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 9 / 13
Version 2

Eye Irritation Rabbit Slight
Skin Sensitization Guinea Pig Negative

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Diclofenac Sodium

30 Day(s) Rat Oral 14 mg/kg LOAEL None identified
5 Week(s) Mouse Oral 9 mg/kg LOAEL Lungs, Spleen
26 Week(s) Rat Oral 50 mg/kg LOAEL Blood, Gastrointestinal system

Carboxymethylcellulose sodium

13 Week(s) Rat Oral 227 g/kg LOAEL Liver, Kidney, Ureter, Bladder

Propylparaben

3 Week(s) Rat Oral 27.1 g/kg LOAEL Endocrine system
4 Week(s) Rat Oral 347.2 mg/kg LOAEL Male reproductive system

Methyl-p-hydroxybenzoate

28 Day(s) Rat Oral 250 mg/kg/day NOAEL Gastrointestinal System, Spleen, Thymus

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Diclofenac Sodium

Embryo / Fetal Development Rat Oral 24 mg/kg LOAEL Maternal toxicity, Fetotoxicity
Embryo / Fetal Development Rat 1 mg/kg LOAEL Developmental toxicity
Embryo / Fetal Development Rat No route specified 20 mg/kg/day Not Teratogenic
Embryo / Fetal Development Rabbit No route specified 10 mg/kg/day NOEL Not Teratogenic

Methyl-p-hydroxybenzoate

Embryo / Fetal Development Rabbit Oral 300 mg/kg/day NOEL Maternal toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Diclofenac Sodium

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Methyl-p-hydroxybenzoate

In Vivo Dominant Lethal Assay Rat Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Diclofenac Sodium

Not specified Rat Oral 2 mg/kg/day NOEL Not carcinogenic

Carcinogenicity See below

Titanium dioxide

IARC Group 2B (Possibly Carcinogenic to Humans)

Povidone

IARC Group 3 (Not Classifiable)

Section 12: ECOLOGICAL INFORMATION

Environmental Overview: May have harmful effects on the aquatic environment. Releases to the environment should be avoided.

12.1. Toxicity

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Diclofenac Sodium

Oncorhynchus mykiss (Rainbow Trout) EC-50 96 hours 130.6 mg/l
Daphnia magna (Water Flea) EC50 48 hours 68 mg/L
Skeletonema costatum (Marine Diatom) ErC50 48 hours 42 mg/l
Skeletonema costatum (Marine Diatom) EC-50 72 Hours 100 mg/L

Methyl-p-hydroxybenzoate

Oryzias latipes (Japanese Rice Fish) OECD LC50 96 hours 59.5 mg/l
Daphnia magna (Water Flea) ISO EC50 48 hours 11.2 mg/L

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 10 / 13
Version 2

12.2. Persistence and degradability

Persistence and degradability

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Diclofenac Sodium

Ready 55 % After 28 Day(s) Not Ready

Methyl-p-hydroxybenzoate

OECD Activated sludge Ultimate (CO2 Evolution) 89 % After 28 Day(s) Ready

12.3. Bioaccumulative potential

Bioaccumulation

Partition Coefficient: (Method, pH, Endpoint, Value)

Diclofenac epolamine

Predicted Log P 4.05

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

Chemical Name	PBT and vPvB assessment
Titanium dioxide	The substance is not PBT / vPvB PBT assessment does not apply
Tartaric acid	The substance is not PBT / vPvB
Propylparaben	The substance is not PBT / vPvB
Methyl-p-hydroxybenzoate	The substance is not PBT / vPvB
Edetate disodium	The substance is not PBT / vPvB
Butylene glycol	The substance is not PBT / vPvB

12.6. Other adverse effects

Other adverse effects No information available.

Section 13: DISPOSAL CONSIDERATIONS

13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 11 / 13
Version 2

Section 15: REGULATORY INFORMATION

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Diclofenac epolamine	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Water	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	231-791-2
AICS	Present
Titanium dioxide	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	carcinogen 9/2/2011 airborne, unbound particles of respirable size
TSCA	Present
EINECS	236-675-5
AICS	Present
Tartaric acid	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	201-766-0
AICS	Present
Sorbitol solution	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	200-061-5
AICS	Present
Sodium polyacrylate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present
Propylparaben	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-307-7
AICS	Present
Povidone	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present
Polysorbate 80	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 12 / 13
Version 2

EINECS	Not Listed
AICS	Present
Methyl-p-hydroxybenzoate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	202-785-7
AICS	Present
Kaolin	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	310-194-1
AICS	Present
Gelatin	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	232-554-6
AICS	Present
Fragrance	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Edetate disodium	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	205-358-3
AICS	Present
Dihydroxyaluminum aminoacetate	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	Not Listed
Carboxymethylcellulose sodium	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	Not Listed
AICS	Present
Butylene glycol	
CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
TSCA	Present
EINECS	203-529-7
AICS	Present

15.2. Chemical safety assessment

Chemical Safety Report No information available

Section 16: OTHER INFORMATION

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

H301 - Toxic if swallowed

H360D - May damage the unborn child

H413 - May cause long lasting harmful effects to aquatic life

SAFETY DATA SHEET

Product Name Diclofenac Epolamine Topical System (Greenstone LLC)
Revision date 15-Jan-2020

Page 13 / 13
Version 2

Prepared By Product Stewardship Hazard Communication
Global Environment, Health, and Safety Operations

Revision date 15-Jan-2020

Reason for revision Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Data Sources: The data contained in this SDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.